Abstract ED03-04: Using epigenetic biomarkers as prognostic and predictive markers in non-small cell lung cancer (NSCLC) and the promise of epigenetic therapy
Malcolm V. Brock(Johns Hopkins University), Charles M. Rudin(Memorial Sloan Kettering Cancer Center), Rosalyn A. Juergens(McMaster University), Igor Espinoza Delgado(Lovelace Respiratory Research Institute), Michelle A. Rudek(Dana-Farber Cancer Institute), Frank P. Vendetti(University of Pittsburgh), Ming Zhao(Sidney Kimmel Comprehensive Cancer Center), James G. Herman(UPMC Hillman Cancer Center), Sara Murphy(The Geneva Foundation), Noreli Franco(Lovelace Respiratory Research Institute), Stephen B. Baylin(Johns Hopkins University), Steven A. Belinsky(Lovelace Respiratory Research Institute), Rosa Sebree(Lovelace Respiratory Research Institute), John Wrangle(Johns Hopkins University), Craig M. Hooker(Lovelace Respiratory Research Institute), Barbara Coleman(Lovelace Respiratory Research Institute), Kristen Rodgers(Johns Hopkins University), Salina Tsai(Lovelace Respiratory Research Institute), Beverly Lee(Lovelace Respiratory Research Institute)
Cited by 0
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Inactivation of the DNA-Repair Gene<i>MGMT</i>and the Clinical Response of Gliomas to Alkylating Agents
|New England Journal of Medicine|2000|2.2k
Incidence and functional consequences of <i>hMLH1</i> promoter hypermethylation in colorectal carcinoma
|Proceedings of the National Academy of Sciences|1998|1.9k